COSCIA, Marta
 Distribuzione geografica
Continente #
NA - Nord America 7.642
EU - Europa 5.583
AS - Asia 2.468
AF - Africa 162
SA - Sud America 37
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 28
Totale 15.952
Nazione #
US - Stati Uniti d'America 7.552
CN - Cina 1.761
IT - Italia 1.312
IE - Irlanda 748
SE - Svezia 717
DE - Germania 633
UA - Ucraina 456
AT - Austria 440
FR - Francia 375
FI - Finlandia 236
KR - Corea 153
GB - Regno Unito 142
IN - India 130
VN - Vietnam 126
SN - Senegal 124
PL - Polonia 114
CA - Canada 84
SG - Singapore 67
JP - Giappone 61
DK - Danimarca 56
ES - Italia 48
HK - Hong Kong 46
BE - Belgio 45
GR - Grecia 44
BY - Bielorussia 40
NL - Olanda 40
RU - Federazione Russa 37
AU - Australia 30
CH - Svizzera 28
EU - Europa 28
IR - Iran 25
TW - Taiwan 25
BR - Brasile 22
CZ - Repubblica Ceca 20
UZ - Uzbekistan 18
RO - Romania 17
EG - Egitto 12
TR - Turchia 11
ZA - Sudafrica 11
TH - Thailandia 8
LU - Lussemburgo 7
SA - Arabia Saudita 7
AR - Argentina 6
HU - Ungheria 5
ID - Indonesia 5
IL - Israele 5
NO - Norvegia 5
PT - Portogallo 5
MX - Messico 4
NG - Nigeria 4
PH - Filippine 4
PK - Pakistan 4
AM - Armenia 3
CL - Cile 3
DZ - Algeria 3
IQ - Iraq 3
MK - Macedonia 3
RS - Serbia 3
UY - Uruguay 3
MA - Marocco 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CO - Colombia 1
EC - Ecuador 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IM - Isola di Man 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
Totale 15.952
Città #
Chandler 1.339
Beijing 1.081
Dublin 748
Vienna 437
Ashburn 404
Ann Arbor 393
Jacksonville 331
Torino 329
Houston 320
Nyköping 300
Fairfield 297
Medford 274
Dearborn 271
Wilmington 235
Princeton 232
Villeurbanne 217
San Mateo 169
Woodbridge 143
Fremont 135
Redwood City 115
Seattle 111
Warsaw 95
Cambridge 89
Milan 85
Dong Ket 83
Turin 75
New York 71
Guangzhou 66
Boston 59
Nanjing 52
Shanghai 52
Hefei 50
Toronto 50
Washington 49
Hangzhou 46
Centro 45
Pisa 42
Norwalk 41
Boardman 38
Düsseldorf 37
Brussels 36
Chengdu 35
Florence 34
Rome 31
Munich 25
Nürnberg 25
Seoul 25
Chennai 24
San Diego 24
Hebei 21
Wuhan 20
Kunming 19
Falls Church 18
Pune 18
Shenyang 18
Taipei 18
Mountain View 17
Singapore 17
San Jose 16
Xian 16
Central District 15
Guiyang 15
Hyderabad 15
Nanchang 15
Phoenix 15
Ottawa 14
Piemonte 14
Tokyo 14
Barcelona 13
Jinan 13
Changsha 12
Hong Kong 12
São Paulo 12
Zhengzhou 12
Linden 11
Columbus 10
Des Moines 10
Jaipur 10
Tianjin 10
Upper Marlboro 10
Bologna 9
Genova 9
Philadelphia 9
Provo 9
Rotterdam 9
Verona 9
Changchun 8
Chicago 8
Dallas 8
Fuzhou 8
Oerlikon 8
Paris 8
Raritan 8
Shaoxing 8
Sydney 8
Wenzhou 8
Wroclaw 8
Codogno 7
Garessio 7
Hamburg 7
Totale 9.878
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 661
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. 437
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 276
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 275
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 269
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22 260
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 190
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 188
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 173
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 172
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 171
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response 155
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 151
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 151
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 132
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 128
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 128
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 127
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 122
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 119
AISF position paper on HCV in immunocompromised patients 118
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 117
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 114
Effective anti-tumor immunomodulatory properties of zoledronic acid 114
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS 112
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 112
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 112
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 110
THE PD-1/PD-L1 AXIS CONTRIBUTES TO T CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA 106
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence 106
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 105
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 105
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 105
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 103
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 100
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 100
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 99
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 98
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 98
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 97
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 97
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 97
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 96
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 93
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 92
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life 92
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 92
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis 91
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 91
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 90
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 89
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 89
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 89
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 89
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 88
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 87
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 87
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 87
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 86
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 86
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 85
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 84
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment 84
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 84
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 83
Immunophenotypic profile and cytogenetic aberrations detected by interphase FISH in B-CLL patients 83
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS 83
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 83
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 83
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 82
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 81
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide 81
null 80
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 80
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 80
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 79
MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY) 79
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 79
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 79
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 78
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 78
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 77
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 77
Real life use of bendamustine in elderly patients with lymphoid neoplasia 77
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells 76
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 76
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma 75
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 75
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells 74
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma 74
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial 74
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene. 74
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID 73
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 72
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 71
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS 71
Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions 71
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study 71
Totale 11.390
Categoria #
all - tutte 45.014
article - articoli 0
book - libri 0
conference - conferenze 23.418
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.432


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019544 0 0 0 0 0 0 0 0 0 169 209 166
2019/20201.958 74 63 82 249 122 324 260 132 123 213 165 151
2020/20212.730 232 188 115 162 365 135 179 174 288 174 397 321
2021/20223.148 157 90 154 269 178 149 404 161 102 304 683 497
2022/20233.721 420 362 98 384 277 902 272 251 398 119 143 95
2023/20241.321 187 306 118 71 110 290 32 150 19 38 0 0
Totale 16.644